Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting
March 14, 2023 20:11 ET
|
Tango Therapeutics, Inc.
BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer...
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank
March 10, 2023 22:15 ET
|
Tango Therapeutics, Inc.
BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics to Participate in Upcoming Investor Conferences
March 01, 2023 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development
February 28, 2023 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics to Participate in Upcoming Investor Conferences
February 02, 2023 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
January 25, 2023 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights
November 10, 2022 07:00 ET
|
Tango Therapeutics, Inc.
– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a...
Tango Therapeutics to Participate in Upcoming Investor Conferences
November 07, 2022 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
October 19, 2022 07:00 ET
|
Tango Therapeutics, Inc.
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,...